Cantor Fitzgerald Decreases Earnings Estimates for Alector

Alector, Inc. (NASDAQ:ALEC) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Alector in a report released on Wednesday, October 22nd. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($1.63) for the year, down from their prior estimate of ($1.53). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($0.81) EPS.

ALEC has been the subject of a number of other research reports. Cowen downgraded Alector to a “hold” rating in a research note on Wednesday. TD Cowen downgraded Alector from a “buy” rating to a “hold” rating in a research note on Wednesday. BTIG Research downgraded Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday. HC Wainwright dropped their price target on Alector from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Wall Street Zen downgraded Alector from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $3.00.

Alector Stock Down 8.7%

ALEC opened at $1.47 on Friday. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $6.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.78 and a current ratio of 3.78. The company has a market capitalization of $148.78 million, a P/E ratio of -1.27 and a beta of 0.99. The stock has a fifty day moving average of $2.79 and a 200-day moving average of $1.88.

Alector (NASDAQ:ALEC) last posted its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%.The company had revenue of $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALEC. Bank of New York Mellon Corp grew its position in Alector by 8.1% in the first quarter. Bank of New York Mellon Corp now owns 249,494 shares of the company’s stock valued at $307,000 after acquiring an additional 18,765 shares during the last quarter. Cerity Partners LLC bought a new position in Alector in the first quarter valued at about $51,000. CWM LLC grew its position in Alector by 370.7% in the first quarter. CWM LLC now owns 33,643 shares of the company’s stock valued at $41,000 after acquiring an additional 26,495 shares during the last quarter. Invesco Ltd. grew its position in Alector by 209.6% in the first quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock valued at $183,000 after acquiring an additional 100,591 shares during the last quarter. Finally, Nuveen LLC bought a new position in Alector in the first quarter valued at about $170,000. Institutional investors own 85.83% of the company’s stock.

Insider Transactions at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of Alector stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the transaction, the director owned 74,909 shares in the company, valued at $176,785.24. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.70% of the stock is currently owned by corporate insiders.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.